Purine and 1-deazapurine ribonucleosides and deoxyribonucleosides: synthesis and biological activity
作者:Gloria Cristalli、Sauro Vittori、Alessandra Eleuteri、Mario Grifantini、Rosaria Volpini、Giulio Lupidi、Laura Capolongo、Enrico Pesenti
DOI:10.1021/jm00111a044
日期:1991.7
6-hydroxylamino derivatives of 1-deazapurine 9, 12, and 17 and also the blocked compound 13 are inhibitors of ADA whereas the purine derivatives 4 and 6 and the nitro compounds 11 and 16 are resistant to the enzyme. 7-(Hydroxylamino)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3H-imi dazo[4,5- b]pyridine, the less cytotoxic but the most active ADA inhibitor in the series (Ki = 2.7 x 10(-7)), greatly potentiates
合成了一系列6-(羟氨基)嘌呤和-1-脱氮嘌呤核苷,并测试了它们的抗肿瘤和腺苷脱氨酶抑制活性。所有检查的分子均显示出与参考化合物6-(羟基氨基)-9-β-D-呋喃呋喃糖基嘌呤(HAPR)和ara-A相当的体外活性,其ID50为0.9 microM至约100 microM。1-脱氮嘌呤9、12和17的6-羟基氨基衍生物以及被保护的化合物13是ADA的抑制剂,而嘌呤衍生物4和6以及硝基化合物11和16对该酶具有抗性。7-(羟氨基)-3-(2-脱氧-β-D-赤-戊呋喃糖基)-3H-咪唑并[4,5-b]吡啶,细胞毒性较小,但是该系列中活性最高的ADA抑制剂(Ki = 2.7 x 10(-7)),可大大增强ara-A的体外抗肿瘤活性。